Intercept Pharmaceuticals, Inc. (ICPT) Given "Buy" Rating at Cowen and Company

Rodiano Bonacci
Settembre 23, 2017

Intercept Pharmaceuticals, Inc. most recently reported earnings per share (EPS) of -$3.46 for the June 2017 versus -$3.14 in the same quarter previous year, representing 10% growth. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 14.52% since September 22, 2016 and is downtrending. Wedbush reissued a buy rating on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. This will give analytical advantage to a shorter-term trader since it pursues the price more intimately, and consequently produces less "lag" as comparison to the longer-term moving average. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. On September 21 the stock rating was downgraded to "Neutral" from "Outperform" in a statement from Wells Fargo. The current consensus recommendation provided by covering analysts is 2.20. Intercept Pharmaceuticals now has an average rating of Hold and an average price target of $174.37. Oppenheimer Holdings, Inc. now has a $200.00 price objective on the biopharmaceutical company's stock. The stock's 50 day moving average is $106.75 and its 200-day moving average is $115.74. BMO Capital Markets initiated the stock with "Outperform" rating in Thursday, April 7 report. The company's quarterly EPS surprised Wall Street by as much as -5% to the downside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates. The business had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Looking at volatility levels, the stock observed volatility of 10.63% in last week and saw volatility 5.90% over the past one month. Cowen & Co maintained the shares of ICPT in report on Tuesday, May 31 with "Outperform" rating.

Covering sell-side analysts have recently weighed in on shares of Intercept Pharmaceuticals, Inc.

TRADEMARK VIOLATION WARNING: This report was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was copied illegally and republished in violation of United States and global trademark & copyright law. On September 22 the company was downgraded to "Neutral" from "Buy" in an announcement from Citigroup.

On Tuesday, July 11th, David Shapiro sold 553 shares of Intercept Pharmaceuticals stock. The recent change has given its price a -34.42% deficit over SMA 50 and -57.39% deficit over its 52-week high. The information was declared in a document with the securities and exchange commission, which is available at this link. The shares were purchased at an average price of $117.43. Similar statistics are true for the second largest owner, Ameriprise Financial Inc, which owns 2,576,729 shares of the stock are valued at $252.83 million. The disclosure for this sale can be found here. DekaBank Deutsche Girozentrale now owns 8,390 shares of the biopharmaceutical company's stock worth $947,000 after buying an additional 5,800 shares during the last quarter.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. WFG Advisors LP increased its holdings in shares of Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company's stock worth $108,000 after acquiring an additional 125 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in Intercept Pharmaceuticals by 223.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company's stock worth $118,000 after purchasing an additional 132 shares during the last quarter. US Bancorp DE acquired a new stake in Intercept Pharmaceuticals during the first quarter worth about $130,000. Intercept Pharmaceuticals has a 12 month low of $60.97 and a 12 month high of $172.95. Emerald Advisers Inc. PA now owns 76,079 shares of the biopharmaceutical company's stock worth $12,522,000 after buying an additional 23,129 shares during the period.

Wellington Management Group Llp increased General Electric Co (GE) stake by 11.89% reported in 2017Q2 SEC filing. However, the institutional investors are observed to own 87.50% of the total shares.

The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE